On November 28, Gelonghui reported that Bailitianheng (688506.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" officially issued by the National Medical Products Administration (NMPA), and the clinical trial for the innovative biopharmaceutical BL-M08D1 (ADC) developed independently by the company has been approved.
BL-M08D1 is an ADC drug that originates from the same small molecule technology platform as BL-B01D1 and shares the same "linker + toxin" platform with BL-B01D1, indicated for recurrent or refractory hematologic malignancies and locally advanced or metastatic solid tumors.
Comment(0)
Reason For Report